Jones Financial Companies’s Structure Therapeutics GPCR Stock Holding History

Jones Financial Companies’s Portfolio GPCR Stock Details GPCR Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q1	$15.7K	Sell	341 -705	-67%	-$48.2K	﹤0.01%	3394
2025 Q4	$72.7K	Buy	1,046 +859	+459%	+$35.1K	﹤0.01%	2356
2025 Q3	$4.67K	Sell	187 -580	-76%	-$11.6K	﹤0.01%	3381
2025 Q2	$16.2K	Sell	767 -2,379	-76%	-$52.3K	﹤0.01%	2687
2025 Q1	$62.2K	Sell	3,146 -1,082	-26%	-$26.5K	﹤0.01%	1978
2024 Q4	$115K	Buy	4,228 +971	+30%	+$34.5K	﹤0.01%	1578
2024 Q3	$136K	Buy	+3,257	New	+$126K	﹤0.01%	1286

Other funds holding GPCR

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return

ACA

Avoro Capital Advisors New York $10.2B AUM 149.19% 1-Year Est. Return

Janus Henderson Group London, United Kingdom $209B AUM 37.72% 1-Year Est. Return

DTC

Deep Track Capital Greenwich, Connecticut $6.12B AUM 144% 1-Year Est. Return

BVF Inc San Francisco, California $3.14B AUM 249.53% 1-Year Est. Return

Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return

T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return

Principal Financial Group Des Moines, Iowa $187B AUM 18.48% 1-Year Est. Return

DCM

Driehaus Capital Management Chicago, Illinois $13.6B AUM 173.98% 1-Year Est. Return

Jones Financial Companies's GPCR Position: Q1 2026 in Review

Jones Financial Companies reduced its Structure Therapeutics (GPCR) stake by 67% in Q1 2026, selling an estimated $48.2K and leaving 341 shares worth $15.7K. The position accounts for ﹤0.01% of the portfolio, ranked #3394.

Jones Financial Companies first reported a position in GPCR in Q3 2024 and has held it in 7 quarters since. The position peaked at $136K in Q3 2024. 196 funds tracked by Wall St. Rank hold GPCR as of Q1 2026.

Jones Financial Companies held 341 shares of Structure Therapeutics worth $15.7K as of Q1 2026.
Jones Financial Companies sold 705 Structure Therapeutics shares in Q1 2026, an estimated $48.2K.
Structure Therapeutics made up ﹤0.01% of Jones Financial Companies's portfolio in Q1 2026, its #3394 holding.
Jones Financial Companies first reported a position in Structure Therapeutics in Q3 2024 and has held it in 7 quarters since.
Jones Financial Companies's Structure Therapeutics position peaked at $136K in Q3 2024.
196 funds tracked by Wall St. Rank held Structure Therapeutics as of Q1 2026.

Based on Jones Financial Companies's 13F filing for Q1 2026, filed 15 May 2026.